Análisis de la cuota de mercado de CinnaGen para julio 2026

CinnaGen Co. was founded in 1994 with the goal of manufacturing hi-tech products in biotechnology and related fields. Since its start of operation with 4 scientists, CinnaGen has grown to become the biggest bio-pharmaceutical manufacturer and biotech exporter in the region. The concept was to be active in the research and development of new potent biotech-based products to cover regional markets. Enzymes, molecular biology reagents and PCR kits were the first products and then CinnaGen used its proprietary set of technologies to endow monoclonal antibodies for blood group typing. The next important step for CinnaGen was to enter therapeutic recombinant protein and monoclonal anti-bodies area. Today the company prides itself in its innovative skills meeting today challenges. We focus our efforts on developing the bio-similar candidates in the areas of immunological diseases, infertility, hormone disorders and oncology as well as providing contract research development services. The company is spending over 20 percent of its total turnover on R&D activities. CinnaGen is strategically positioned to become and remain a leading biotechnology company in the region. Our aim is to use our expertise to identify and acquire selected products through strategic partnerships to promote sustainable development in human health.